The scientist’s investigation covers issues in Internal medicine, Lung cancer, Oncology, Gefitinib and Surgery. Erlotinib, Chemotherapy, Hazard ratio, Gemcitabine and Carboplatin are among the areas of Internal medicine where Caicun Zhou concentrates his study. His work carried out in the field of Lung cancer brings together such families of science as Cancer research, Chemotherapy regimen, Clinical trial, Gastroenterology and Carcinoma.
He interconnects Epidermal growth factor receptor and Pathology in the investigation of issues within Oncology. Caicun Zhou has researched Surgery in several fields, including Icotinib and Tolerability. His study in Afatinib is interdisciplinary in nature, drawing from both Rociletinib and Pemetrexed.
Caicun Zhou focuses on Internal medicine, Lung cancer, Oncology, Chemotherapy and Cancer research. His work is dedicated to discovering how Internal medicine, Surgery are connected with Gastroenterology and other disciplines. His Lung cancer research is multidisciplinary, incorporating elements of Cancer, Epidermal growth factor receptor and Adenocarcinoma.
His Oncology research includes themes of Gemcitabine and Immunotherapy. His Chemotherapy research is multidisciplinary, incorporating elements of Clinical endpoint, Adverse effect and Afatinib. His research in Cancer research focuses on subjects like Immunohistochemistry, which are connected to Tumor-infiltrating lymphocytes.
His main research concerns Lung cancer, Internal medicine, Oncology, Cancer research and Immunotherapy. His Lung cancer research includes elements of Epidermal growth factor receptor, Tumor microenvironment, CD8, Immune checkpoint inhibitors and Metastasis. His works in Chemotherapy, non-small cell lung cancer, Incidence, Combination therapy and Stage are all subjects of inquiry into Internal medicine.
His studies in Oncology integrate themes in fields like Adverse effect, Targeted therapy, Clinical trial and Cohort. His research investigates the link between Cancer research and topics such as Cancer that cross with problems in Immunology and Human leukocyte antigen. His research integrates issues of Biomarker, Cytotoxic T cell, Radiation therapy and Pneumonitis in his study of Immunotherapy.
Caicun Zhou mostly deals with Lung cancer, Cancer research, Internal medicine, Oncology and Immunotherapy. His studies deal with areas such as Adverse effect, Pediatrics and Adenocarcinoma as well as Lung cancer. The study incorporates disciplines such as Cancer, Metastasis, Epidermal growth factor receptor, Tumor-infiltrating lymphocytes and Osimertinib in addition to Cancer research.
His Chemotherapy and Carboplatin investigations are all subjects of Internal medicine research. His work on Non small cell as part of general Oncology research is frequently linked to In patient, thereby connecting diverse disciplines of science. The various areas that Caicun Zhou examines in his Immunotherapy study include Cytotoxic T cell, CD8 and Ligand.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
Caicun Zhou;Yi Long Wu;Gongyan Chen;Jifeng Feng.
Lancet Oncology (2011)
Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer
Jean-Charles Soria;Yuichiro Ohe;Johan Vansteenkiste;Thanyanan Reungwetwattana.
The New England Journal of Medicine (2018)
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
Tony S.K. Mok;Yi Long Wu;Iveta Kudaba;Dariusz M. Kowalski.
The Lancet (2019)
Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial
Yi-Long Wu;Caicun Zhou;Cheng-Ping Hu;Jifeng Feng.
Lancet Oncology (2014)
Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial
Vincent A. Miller;Vincent A. Miller;Vera Hirsh;Jacques Cadranel;Yuh Min Chen.
Lancet Oncology (2012)
Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC
Suresh S Ramalingam;Johan Vansteenkiste;David Planchard;Byoung Chul Cho.
The New England Journal of Medicine (2020)
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
James Chih Hsin Yang;Yi Long Wu;Martin Schuler;Martin Sebastian.
Lancet Oncology (2015)
Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
Luis Paz-Ares;Mikhail Dvorkin;Yuanbin Chen;Niels Reinmuth.
The Lancet (2019)
Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6.
James C.H. Yang;Lecia V. Sequist;Sarayut Lucien Geater;Chun Ming Tsai.
Lancet Oncology (2015)
First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study
Y.-L. Wu;C. Zhou;C.-K. Liam;G. Wu.
Annals of Oncology (2015)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: